Yazar "Karasu, Zeki" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim
    Öğe
    Covid-19 in liver transplant recipients: A national cohort
    (Elsevier, 2021) Kabaçam, Gökhan; Turan, İlker; Kıyıcı, Murat; Melekoğlu Ellik, Zeynep; Dolu, Süleyman; Dayangaç, Murat; Arı, Derya; Turan Gökçe, Dilara; Yıldırım, Abdullah Emre; Gençdal, Genco; Harputluoğlu, Murat; Kartal, Aysun; Dindar Demiray, Emine Kübra; Gündüz, Feyza; Ergenç, İlkay; Efe, Cumali; Sümer, Hale Gökcan; Akdoğan Kayhan, Meral; Gülşen, Murat Taner; Akyıldız, Murat; Arıkan, Ciğdem; Arıkan, Çiğdem; Karademir, Sedat; Balcı, Deniz; Dündar, Ziya; Akarsu, Mesut; Günşar, Fulya; Karasu, Zeki; İdilman, Ramazan
    Introduction: The effect of coronavirus disease 2019 (COVID-19) on outcomes of liver transplant recipients is not known very well. Aim: Methods The aim of the present study was to describe the early outcomes of liver transplant recipients with COVID-19.
  • Küçük Resim Yok
    Öğe
    Outcomes following deceased and live donor liver transplantation for the indication of acute liver failure: A multicenter experience
    (Lippincott Williams & Wilkins, 2021) Turan, İlker; Akarsu, Mesut; Aladass, M.; Harputluoğlu, Murat; Yılmaz, Sezai; Gençdal, Genco; Akyıldız, Cengiz; Polat, Kamil Yalçın; Özçay, Figen; Ünek, Tarkan; Karasu, Zeki; Zeytunlu, Murat; Gökcan Sümer, Hale; Bostancı, Erdal Birol; Çalışkan Kartal, Aysun; Balcı, Deniz; Dayangaç, Murat; Dinçer, Didem; Adanır, Haydar; Dursun, Hakan; Gülşen, Murat Taner; Gündüz, Ferhan; Balaban, Hatice Yasemin; Kabaçam, Gökhan; Akyıldız, Muhammet Ali; Gunssar, F.; Akarca, Ulus Salih; Gürakar, Ahmet; İdilman, Ramazan
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience
    (AVES, 2020) Değertekin, Bülent; Demir, Mehmet; Akarca, Ulus S.; Kani, Haluk Tarık; Üçbilek, Enver; Yıldırım, Emre; Güzelbulut, Fatih; Balkan, Ayhan; Vatansever, Sezgin; Danış, Nilay; Demircan, Melek; Soylu, Aliye; Yaraş, Serkan; Kartal, Aysun; Kefeli, Ayşe; Gündüz, Feyza; Yalçın, Kendal; Erarslan, Elife; Aladağ, Murat; Harputluoğlu, Murat; Özakyol, Ayşegül; Temel, Tuncer; Akarsu, Mesut; Sümer, Hale; Akın, Mete; Albayrak, Bülent; Şen, İlker; Alkım, Hüseyin; Uyanıkoğlu, Ahmet; Irak, Kader; Öztaşkın, Sinem; Uğurlu, Çağrı Burak; Güneş, Şevkican; Gürel, Selim; Nuriyev, Kenan; İnci, İsmail; Kaçar, Sabite; Dinçer, Dinç; Doganay, Levent; Göktürk, Hüseyin Savaş; Mert, Ali; Coşar, Arif Mansur; Dursun, Hakan; Atalay, Roni; Akbulut, Sabiye; Balkan, Yasemin; Köklü, Hayrettin; Şimşek, Halis; Özdoğan, Osman; Çoban, Mehmet; Poturoğlu, Şule; Ayyıldız, Talat; Yapalı, Suna; Günşar, Fulya; Akdoğan, Meral; Özenirler, Seren; Akyıldız, Murat; Sezgin, Orhan; Özdoğan, Osman; Kaymakoğlu, Sabahattin; Beşışık, Fatih; Karasu, Zeki; İdilman, Ramazan
    Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population.Material and Methods: A total of 4,352 patients with CHC from 36 different institutions in Turkey were enrolled. They received ledipasvir (LDV) and sofosbuvir (SOF)+/- ribavirin (RBV) ombitasvir/paritaprevir/ritonavir +/- dasabuvir (PrOD)+/- RBV for 12 or 24 weeks. Sustained virologic response (SVR) rates, factors affecting SVR, safety profile, and hepatocellular cancer (HCC) occurrence were analyzed.Results: SVR12 was achieved in 92.8% of the patients (4,040/4,352) according to intention-to-treat and in 98.3% of the patients (4,040/4,108) according to per-protocol analysis. The SVR12 rates were similar between the treatment regimens (97.2%-100%) and genotypes (95.6%-100%). Patients achieving SVR showed a significant decrease in the mean serum alanine transaminase (ALT) levels (50.90 +/- 54.60 U/L to 17.00 +/- 14.50 U/L) and model for end-stage liver disease (MELD) scores (7.51 +/- 4.54 to 7.32 +/- 3.40) (p<0.05). Of the patients, 2 were diagnosed with HCC during the treatment and 14 were diagnosed with HCC 37.0 +/- 16.0 weeks post-treatment. Higher initial MELD score (odds ratio [OR]: 1.92, 95% confidence interval [CI]: 1.22-2.38; p=0.023]), higher hepatitis C virus (HCV) RNA levels (OR: 1.44, 95% CI: 1.31-2.28; p=0.038), and higher serum ALT levels (OR: 1.38, 95% CI: 1.21-1.83; p=0.042) were associated with poor SVR12. The most common adverse events were fatigue (12.6%), pruritis (7.3%), increased serum ALT (4.7%) and bilirubin (3.8%) levels, and anemia (3.1%).Conclusion: LDV/SOF or PrOD +/- RBV were effective and tolerable treatments for patients with CHC and with or without advanced liver disease before and after liver transplantation. Although HCV eradication improves the liver function, there is a risk of developing HCC.
  • Küçük Resim
    Öğe
    Recommendations for hepatitis B immunoglobulin and antiviral prophylaxis against hepatitis B recurrence after liver transplantation
    (AVES, 2021) Akarsu, Mesut; Önem, Soner; Turan, İlker; Adalı, Gupse; Akdoğan, Meral; Akyıldız, Murat; Aladağ, Murat; Balaban, Yasemin; Danış, Nilay; Dayangaç, Murat; Gençdal, Genco; Gökcan, Hale; Sertesen, Elif; Gürakar, Merve; Harputluoğlu, Murat; Kabaçam, Gökhan; Karademir, Sedat; Kıyıcı, Murat; İdilman, Ramazan; Karasu, Zeki
    The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t)ide analogs after liver transplantation.
  • Küçük Resim
    Öğe
    The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists
    (AVES, 2020) Kabaçam, Gökhan; Dayangaç, Murat; Üçbilek, Enver; Erçin, Cemal Nuri; Günsar, Fulya; Akyıldız, Murat; Akarsu, Mesut; Demir, Mehmet; Kaymakoğlu, Sabahattin; Karasu, Zeki; İdilman, Ramazan
    Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel acute infectious disease that has rapidly reached staggering pandemic proportions. This review addresses gastroenterologists, hepatologists, liver transplant (LT) specialists, and health-care professionals working in the field of liver diseases and liver transplantation. It has been written based on a limited number of publications, recommendations of national and international liver and organ transplantation societies, and experiences of patients with COVID-19 around the world. The purpose of this review is to provide information addressing questions and concerns about COVID-19, to reveal the effects of the novel disease on patients with chronic liver disease and LT recipients, and to share information about ways in which this pandemic will affect clinical practices. We, the Turkish Association for the Study of the Liver (TASL), would like to remind you that this text is actually not a practical guide. It is imperative to act according to the standards set by health-care institutions and the Ministry of Health, Republic of Turkey.